Research Paper
40Hz gamma entrainment wearable reduces Alzheimer's biomarkers: 12-month extension results
PubMed4/16/2026·04/16/26🌐 USA
Summary
Cognito Therapeutics' Phase 2 OVERTURE 12-month extension showed continued amyloid and tau reduction via PET imaging and slowed cognitive decline versus sham in 76 early Alzheimer's patients receiving 40Hz light and sound stimulation daily.
Why it matters
A non-invasive device showing 12-month biomarker reduction and cognitive slowing in Alzheimer's is remarkable and is expected to support a Phase 3 pivotal trial design.
#Alzheimers#Biomarkers#Neurostimulation#Wearables
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in